Related Experiment Video
Updated: Sep 22, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Joint Effect of Multiple Prothrombotic Genotypes and Mean Platelet Volume on the Risk of Incident Venous
Lisa Jakobsen1, Tobias Frischmuth1,2, Sigrid K Brækkan1,2
1Department of Clinical Medicine, Thrombosis Research Center, UiT-The Arctic University of Norway, Tromsø, Norway.
Background:
A high mean platelet volume (MPV), a marker of increased platelet reactivity, is a risk factor for venous thromboembolism (VTE). Whether established prothrombotic single nucleotide polymorphisms (SNPs) further increase the VTE risk in subjects with high MPV because of biological interaction remains unknown.
Aim:
To investigate the joint effect of high MPV and prothrombotic genotypes, comprising a 5-SNP genetic risk score (GRS), on the risk of VTE in a population-based case-cohort.
Methods:
Incident VTE cases (n = 653) and a subcohort (n = 1,774) were derived from the Tromsø Study (1994-2012). DNA was genotyped for rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2036914 (F11), and rs2066865 (FGG). Hazard ratios (HRs) for VTE with 95% confidence intervals (CIs) were estimated according to predefined MPV-strata (<8.5, 8.5-9.5, ≥9.5 fL) and number of risk alleles for each individual SNP and the GRS (0-1, 2-3, ≥4 risk alleles) in models adjusted for age, sex, body mass index, and platelet count.
Results:
The combination of high MPV and risk alleles, either as individual SNPs or the GRS, had an additive effect on VTE risk. Compared with subjects with MPV <8.5 fL and 0-1 risk allele, those with high MPV (≥9.5 fL) and ≥4 risk alleles had HRs of 2.80 (95% CI: 1.77-4.43) for overall VTE and 4.60 (95% CI: 2.20-9.60) for unprovoked events, respectively, but there was no supra-additive effect on risk estimates.
Conclusion:
The combination of high MPV and prothrombotic genotypes had an additive effect on VTE risk, suggesting there is no biological interaction between these risk factors in the pathogenesis of VTE.
More Related Videos
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

